Tagantidepressant

Reading of the Week: Antidepressants after Acute Coronary Syndrome and Depression – A Lifesaver? The New JAMA Paper

From the Editor

State-of-the-art care for acute coronary syndrome includes oxygen and clot-busting drugs. Should it also include a depression screen and an antidepressant if necessary?

In this week’s Reading, we look at a new JAMA paper showing a response to escitalopram for patients post-ACS (Acute Coronary Syndrome) with depression. Though work has been done in this area before, this paper is an important contribution: it’s well designed, and offers a long follow-up period. Chonnam National University Medical School’s Jae-Min Kim and his co-authors conclude: “In this median 8.1-year follow-up of a randomized 24-week clinical trial of treatment for depression in patients with recent ACS, MACE [major adverse cardiac event] incidence was significantly lower in patients receiving escitalopram than those receiving placebo.”

We consider the paper and its implications.

norm_2xGood EKG, good antidepressant?

Please note that there will be no Readings for the next two weeks.

DG
Continue reading

Reading of the Week: Depression and Its Management — The American Journal of Psychiatry on Exercise and Long-term Use of Medication

From the Editor

It’s one of the most common and disabling illnesses. But how to treat depression in the long term?

In the first selection, we consider a paper just published by The American Journal of Psychiatry. In it, LaSalle University’s Felipe B. Schuch and his co-authors present a meta-analysis on exercise and depression. Drawing on 49 studies, they find that physical activity can protect against the development of depression, regardless of age and geographical region.

treat-alternative-exercise_an_alternative_adhd_treatment-article-3280a-man_running_sunset-ts_451886305-3Exercise: good for the heart, the lungs, and the prevention of depression?

In the second selection, Harvard University’s Roy H. Perlis writes a commentary for The American Journal of Psychiatry responding to a recent New York Times article that questioned the long-term use of antidepressants. He writes: “The informative analogy might be treatment of type 2 diabetes. While diet and exercise have a substantial impact on disease course (notably, results far more compelling than those in depression), it is hard to envision front-page articles in the New York Times about the dangers of long-term diabetes treatment.”

DG

Continue reading

Reading of the Week: The Big NYT Article on Antidepressants & Withdrawal – Our Vioxx Moment?

From the Editor

“Many People Taking Antidepressants Discover They Cannot Quit.”

The New York Times. Front page. Sunday edition.

One of the most read newspapers in the world just ran a story suggesting that antidepressants may be linked to significant withdrawal symptoms. That news article is, well, news. Journalists Benedict Carey and Robert Gebeloff interview a mother of four who says, “Had I been told the risks of trying to come off this drug, I never would have started it.”

istock_000017711523xlargeAntidepressants: small pills but big problem?

This week’s Reading looks at the big article and considers its big implications.

DG

Continue reading

Reading of the Week: Do Antidepressants Work? The New Cipriani Study

From the Editor

Last week, I spoke to a patient about antidepressants. “But do they really work?” she asked. While antidepressants are commonly prescribed, many patients wonder about them. That’s not surprising: in popular culture, these medications are often portrayed as risky and unhelpful. Just a few weeks ago, the most popular women’s fitness magazine in the world described fawningly how a woman quit her medications and felt better (“I felt more alive and in control of my emotions with each passing day”). A few years ago, a major study suggested that antidepressants basically match placebo in efficacy; 60 Minutes covered it.

And now there is the new Cipriani et al. paper. “We found that all antidepressants included in the meta-analysis were more efficacious than placebo in adults with major depressive disorder…”

Is this the biggest psychiatry paper of the year? Certainly, it may be one of the most impressive. It took six years of effort. Oxford University’s Andrea Cipriani and his co-authors drew from all available data – published and unpublished, and covering more than 500 trials.

The media coverage has been incredible. The Guardian summarized the paper with the first two words of its article: “Antidepressants work.”

645x400-1519289756533

In this Reading, we look at the big study and mull the big implications.

DG

Continue reading

Reading of the Week: “The Secret to My Success? Antidepressants”

From the Editor

With the end of the academic year and the start of the new one, I’ll spend the next few days updating the distribution lists for the Reading of the Week series. I’m using this opportunity to make a few technical changes, too. This is the Reading of the Week equivalent of a spring clean-up – though it’s July, and I’m not touching a dustpan.

Spring cleaning, at least before computers

In any clean-up, we can mistakenly throw away something valuable – it’s possible that some of you may stop receiving these emails (if you are getting our emails). If that happens and you would like to continue to get the Readings, simply pop me a message.

This week, I’ve picked an entertaining and yet moving essay from writer Julia Fierro talking about her illness and her recovery. Enjoy.

Oh, and congratulations to our colleagues who have finished their studies. I hope you enjoy your career in medicine as much as I have.

DG

Continue reading

Reading of the Week: Of Pills and Placebo – The Pecina et al. paper

High rates of placebo responses are consistently reported across medical conditions, notably mood disorders, Parkinson disease, and pain, but also schizophrenia, substance use disorders, and surgical procedures. Placebo response rates in antidepressant trials average 31% to 45% compared with approximately 50% responses to antidepressants, and they have increased over the last 30 years. The failure of antidepressant responses to separate from placebo has contributed to the reduction or discontinuation of research on new treatments for depression and other neuropsychiatric illnesses, hindering the development of novel neuropsychiatric treatments.

So begins a new paper considering the relationship between placebo and depression treatment.

This week’s Reading: “Association Between Placebo-Activated Neural Systems and Antidepressant Responses Neurochemistry of Placebo Effects in Major Depression” by Dr. Marta Peciña et al., which was just published “online first” by JAMA Psychiatry.

Dr. Marta Peciña

Here’s a quick summary: this is a big paper in a big journal that seeks to better understand the placebo effect and antidepressants, and taps neuroimaging to do so. There is, however, a catch: the number of patients involved is small. Continue reading